CRVO - CIK 0001053691
CervoMed Inc. trades as CRVO. In its fiscal 2025 annual report the company posted revenue of $4.01M, down 58.9% from the prior year and net income of -$26.97M. This page tracks CervoMed Inc. through 962 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 15 fiscal years CervoMed Inc.'s revenue grew from $40.19K to $4.01M, a compound annual growth rate of 35.9%. Net profit margin compressed from -30.4% to -673.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-11 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| Major company event | 8-K | 2026-04-22 |
| SCHEDULE 13G/A | - | 2026-04-07 |
| Major company event | 8-K | 2026-04-07 |
The largest companies sharing CervoMed Inc.'s SEC industry classification (pharmaceutical preparations).
CervoMed Inc. reported revenue of $4.01M for fiscal year 2025, a decrease of 58.9% year over year.
In its latest fiscal year CervoMed Inc. reported a net loss of $26.97M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.